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Abstract: Chemically modified allergens (allergoids) have found use in both traditional
and novel forms of immunotherapy of allergic disorders. Novel forms of immu-
notherapy include local allergen delivery, via the gastrointestinal tract. This study con-
veys the gastrointestinal stability of three types of mugwort pollen allergoids under sim-
ulated conditions of the gut. Allergoids of the pollen extract of Artemisia vulgaris were
obtained by means of potassium cyanate, succinic and maleic anhydride. Gastrointesti-
nal tract conditions (saliva, and gastric fluid) were simulated in accordance with the EU
Pharmacopoeia. The biochemical and immunochemical properties of the derivatives
following exposure to different conditions were monitored by determining the number
of residual amino groups with 2,4,6-trinitrobenzenesulfonic acid, SDS PAGE, immuno-
blotting and inhibition of mugwort-specific IgE. Exposure to saliva fluid for 2 min did
not influence the biochemical and immunochemical properties of the derivatives. In the
very acidic conditions of the simulated gastric fluid, the degree of demaleylation and
desuccinylation, even after 4 h exposure, was low, ranging from 10 to 30 %. The diges-
tion patterns with pepsin proceeded rapidly in both the unmodified and modified sam-
ples. In all four cases, a highly resistant IgE-binding protein the Mw of which was about
28 – 35 kD, was present. Within the physiological conditions, no new IgE binding
epitopes were revealed, as demonstrated by immunoblot and CAP inhibition of the
mugwort specific IgE binding. An important conclusion of this study is the stability of
the modified derivatives in the gastrointestinal tract of patients, within physiological
conditions. The means that they are suitable for use in much higher concentrations in lo-
cal forms of immunotherapy than unmodified ones.
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Abbreviations: SF (simulated saliva fluid), SGF (simulated gastric fluid), Av (Arte-
misia vulgaris = mugwort pollen extract), M-Av (maleylated derivatives of the
mugwort pollen extract), S-Av (succinylated derivatives of the mugwort pollen ex-
tract), C-Av (carbamylated derivatives of the mugwort pollen extract), PBS (phos-
phate buffered saline), SLIT-sublingual local immunotherapy.
INTRODUCTION
Various forms of chemically modified allergens, or genetically engineered re-
combinant allergens have been developed1,2 in order to improve the safety and ef-
ficiency of conventional specific immunotherapy.
The principal aproach to allergen modification is to modify B cells epitopes in or-
der to prevent IgE binding and effector cell cross-linking while preserving T cell
epitopes. In this way, the modified allergen will be directed to T cells by a phagocy-
tosis/pinocytosis-mediated antigen uptake mechanism, bypassing IgE cross-linking
and IgE-dependent antigen presentation.3 Thereby, all side-effects of the IgE cro-
ss-linking by an allergen on the effector cells of the immune system, such as histamine
and mediator release, would be diminished in the case of allergoid immunotherapy,
while the protective immune response via the preserved T helper (Th) cell epitopes
would be enhanced during the course of immunotherapy.4
Previous forms of chemically modified allergens were of high molecular
weight2,3 and were unable to pass mucosal barriers and reach the immune system
of patients when applied via local routes.
Low-molecular weight (LMW) derivatives of allergens are modified allergens
of the same (native) size as unmodified ones, with the potential to be used in local
forms of immunotherapy.5–7 They can be obtained by carbamylation8–10 and treat-
ment by maleic or succinic anhydrides.11,12 Moreover, the conversion of allergens
into highly negative (acidic) derivatives could direct them to scavenger receptors
(SRs), specific for highly negative molecular species, modulating the immune re-
sponse towards the Th1 type.13 This type of immune modulation was shown for
some maleylated or acetylated proteins and peptides.14 Therefore, the maleylated
allergens can be considered as having a potential immunostimulatory effect on the
immune system. Their mode of action would not only be the reduction of an imme-
diate phase response, but would also be effective at the T cell level.
All three types of LMW allergoids showed reduced allergenicity in the skin
prick testing of allergic patients.12 A study of the pharmacokinetics of carbamy-
lated allergoids suggested that these derivatives might be protected against proteo-
lytic cleavage, and showed that they attained even higher levels in blood samples
after bucal administration than the unmodified proteins.15
In a previous study16 incomplete hydrolysis of mugwort pollen allergens and
allergoids were observed under simulated gastrointestinal conditions, while reten-
tion of the IgG binding was monitored in an ELISA (enzyme linked immunosorbent
assay), after exposure to the acidic conditions of the gut. Allergoids, particularly
those derived from pollen extracts, have been successfully established as prepara-
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tions for subcutaneous injection immunotherapy. Asurge of interest in local routes of
immunotherapy, particularly sublingual/oral, raises the question as to the suitability
of allergoids for this application. Stability under the various conditions encountered
in the digestive tract is one consideration. Hence, the aim of this study was to
investgate the susceptibility of various Artemisia vulgaris allergoids to degradation.
RESULTS
The effect of saliva fluid on the allergen and allergoids of mugwort pollen extract
Exposure to the simulated saliva fluid for 2 min did not influence the biochem-
ical and physicochemical properties of the allergen and allergoids, as demonstrated
by the measurement of the residual amino groups by the 2,4,6-trinitrobenze-
nesulfonic acid (TNBS) method17 and the protein pattern by SDS PAGE and IEF
(results not shown). Although the results were negative, this feature of the modi-
fied derivatives is beneficial from the point of view of local delivery (sublingual).
The effect of the acidic pH of the simulated gastric fluid on the allergen and
allergoids of Av
The effect of the acidic conditions on the acylated derivatives, which are prone
to acid hydrolysis, was monitored by measuring the number of amino groups by
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Fig. 1. Determination of the amino group number in mugwort pollen extract (Av) and allergoid
samples of maleylated proteins (M), succinylated proteins (S), carbamylated proteins (C) exposed
to the acidic conditions of the SGF (without the addition of pepsin) for one and four hours. The
amino groups were quantified by the TNBS method. The number of amino groups in the unmodi-
fied (Av) sample was regarded as 100 % of the amino group number, while the number of amino
groups determined in the modified samples were calculated relative to the unmodified sample (in
% of the control, unmodified sample). The protein modification which acts on the amino group
leads to the decrease in the detected amino group number.
the TNBS method (Fig. 1). The Av sample demonstrated a decrease in the number
of free amino groups, presumably due to denaturation of the proteins in the very
acidic conditions, leading to aggregation and precipitation, while a slight increase
in the number of free amino groups was registered in the case of the succinyl deriv-
ative. With the carbamylated and maleylated derivatives, the number of free amino
groups did not change significantly. With the maleylated sample, one-hour hydro-
lysis led to a reduction in the number of amino groups which intensified with pro-
longation of the exposure, probably, in part, due to the effect of denaturation. The
extents of demaleylation and desuccinylation, even after 4 h exposure, were very
low, ranging from 10 to 30 %.
Digestion pattern under simulated gastric conditions
Prolonged exposure of the allergens of Av to simulated gastric conditions (for
1 and 4 h), leads to rapid proteolysis of the proteins by pepsin (Fig. 2). The pattern
seen after 30 s of exposure was the same as after 1 h (results not shown). A highly
resistant protein, Mw of about 28 to 35 kD, could be seen in the Av extract and the
KCNO treated proteins. The digested maleylated and succinylated proteins gave
hardly visible peptides, Mw of about 5–15 kD. The majority of the allergens in the
Av and carbamoylated samples were fully degraded by pepsin. The acidic deriva-
tives (M-Av and S-Av) appeared apparently more susceptible to pepsin digestion
(the samples treated for 1 h with SGF). After prolongation of the exposure to the
gastric conditions, and probably through the effect of deamidation at very acidic
pH, the resistant protein bands also appeared in the modified samples. The expla-
nation could be that the dye binding properties of the allergens changed when they
became highly acidic. An acidification of the proteins in all three allergoid prepa-
rations led to a lower dye binding, when compared to the ummodified proteins, due
to a blocking reaction on the lysine residual group.18,19
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Fig. 2. SDS PAGE on 18 % gel of mugwort pollen proteins and allergoids exposed to the acidic
conditions of the gut for 1 and 4 h and to the simulated gastric fluid for one (1h*) and 4 h (4h*),
applied in sequence after the appropriate controls: mugwort pollen extract (Av), maleylated pro-
teins (M), succinylated proteins (S), carbamylated proteins (C): P – pepsin control; M – molecu-
lar weight markers. The proteins were visulized by Coomassie Brilliant Blue R250 staining.
The effects of acidic conditions and the SGF on IgE binding properties of allergens
and allergoids in immunoblot
The proteins of the Av allergen and the allergoids were digested in the simu-
lated gastric conditions and resolved by SDS PAGE. In the immunoblotting with
the sera of the allergic patients it was shown that the SGF resistant proteins bind
IgE from the patients' sera (Fig. 3). Although to a lower extent, the C-Av derivative
behaves in a smilar way, with retention of the 30 kD IgE binding band. The expo-
sure time does not influence the intensity of the band. The derivatives treated with
acid anhydrides completely lacked the IgE binding bands. Digestion with SGF
does not influence the pattern of IgE binding, but acidic conditions do. After 4 h
exposure to gastric conditions, a scarcely visible band of the same weight appeared
in both the S-Av and M-Av derivatives, regardless of whether treated with SGF, or
just exposed to acidic conditions.
CAP inhibition
The effect of the simulated in vitro conditions were quantified by CAP inhibi-
tion (Fig. 4). A pool of the patients' sera was preincubated with allergens, aller-
goids or control proteins, and the residual mugwort pollen specific IgE was quanti-
fied by UniCap. Saliva fluid exposure did not influence the IgE binding in any
case. There appeared to be a high percentage of residual IgE binding activity in the
Av extract, after exposure to SGF (the decrease seen was slightly over 20 %), due
to the high IgE binding potential of the residual allergens, which correlated with
the binding pattern seen in the immunoblot (Fig. 3). Presumably, smaller peptide
fragments may also inhibit the binding of the mugwort specific IgE. SGF exposure
of the maleylated sample led to a small decrease in the IgE binding, while the IgE
binding potential of the succinylated sample did not change on digestion. The
carbamylated sample mostly resembled the unmodified sample, except that IgE
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Fig. 3. Determination of the IgE binding bands on a nitrocellulose membrane after SDS PAGE on
an 18 % gel of mugwort pollen extracts and allergoids, exposed to the acidic conditions of the gut
for 1 and 4 h, and to the simulated gastric fluid for one (1h*) and 4 (4h*), applied in sequence af-
ter the appropriate controls: mugwort pollen extract (Av), maleylated proteins (M), succinylated
proteins (S), carbamylated proteins (C). The resolved proteins were probed with the allergic pa-
tients' sera and bound IgE was detected with monoclonal anti IgE antibody alkaline phosphatase
labeled. The bands were visualized using a precipitating substrate for alkaline phosphatase
(BCIP/NBT), as described in the experimental.
binding potential was lower, which was also the case with acyl derivatives, when
compared to the unmodified extract, in any case under the examined conditions
(untreated samples, samples treated with acidic conditions and samples exposed to
SGF conditions). The results obtained by CAP inhibition are in accordance with
the liberation of a small percent of amino groups in acidic conditions (Fig. 1).
Presumbly, as there was no significant deamidation in the modified Av derivatives
(Fig. 1), there was no significant regeneration of IgE binding epitopes (demon-
strated in the immunoblot and CAP inhibition of the IgE binding to the mugwort
disc). This is an important finding from the aspect of allergoid safety in local
immunotherapy trials.
DISCUSSION
Local allergen delivery has lately become an important route of specific
immunotherapy administration. Modified derivatives of allergens of native molec-
ular size have also been introduced in immunotherapy of allergic diseases in
adults5, 7 and children.8 Acid anhydride derivatives were also considered to have a
potential for use in this form of immunotherapy.12
A modified derivative introduced through local routes may finally reach pa-
tients' gastrointestinal tract and become exposed to very different environments. A
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Fig. 4. Determination of IgE binding potencies of mugwort pollen extract (Av) and allergoids
(maleylated proteins (M), succinylated proteins (S), carbamylated proteins (C)) treated with sa-
liva fluid (SF), simulated gastric fluid (SGF) by means of CAP inhibition of the mugwort pollen
specific IgE.
protective effect on the digestion by a chemical modificiation might occur,17 as
well as a limited hydrolysis, leading to revealing of some IgE binding epitopes by
exposure to (especially) acidic conditions of the gut.
It has been demonstrated that saliva fluid does not influence the allergenic
properties of native and modified derivatives. In sublingual forms of SLIT, a 2 min
absorption through the mucosa will not change the properties of the derivatives in-
troduced. This is an important finding, considering possible side-effects of SLIT
on the mouth, such as itching and edema.2,20 The demonstrated stability of the de-
rivatives tested can be of importance in local allergoid delivery.
The derivatives finally reach the patent's gut and the effects of exposure to these
conditions was affected by the chemical modifications, although to a less extent than
expected. By monitoring the course of -amino group regeneration in a highly acidic
environment, it was noticed that no significant deamidation occurred (Fig. 1). The
deamidation reaction occurred to no more than 30 % of the sample during exposure for
one hour. Prolongation of the exposure did not facilitate the process. According to the
presented results, it was not possible to demonstrate any significant protective effect of
amino group modification from the digestion pattern with pepsin (Fig. 2).
Contrary to a general belief that pollen extracts are quite labile to proteoly-
sis,21,22 the presence of protein bands at about 28 – 35 kD were evidenced in the
mugwort pollen extract treated with pepsin. These resistant Artemisia vulgaris pro-
teins contain intact IgE-binding epitopes and several potential enzymes cut sites
which are protected from the enzyme, probably by the compact structure of the
protein and/or glycosylation. This is the first report of pepsin resistant proteins
from a pollen source. Therefore, hitherto, there were no data on the clinical signifi-
cance of these findings on the higher incidence of gastrointestinal side-effects dur-
ing local immunotherapy to the mugwort extract. However, in the case of an aller-
gen source which is resistant to pepsin-digestion, modified derivatives of reduced
capacity to bind specific IgE could be recommended. According to the presented
results, the IgE binding is not restored in the modified derivatives after exposure to
simulated gastric conditions (Figs. 3 and 4). Therefore, they could be regarded as a
safe immunotherapy option for application in local allergen delivery.
EXPERIMENTAL
Allergen and allergoids preparations
The pollen samples, obtained from the Institute for Immunology and Virology, Torlak, Bel-
grade, Serbia, were collected from mugwort weed collected in the outskirts of Belgrade. The pollen
extracts, as well as the modified derivatives, were prepared as described previously.12 A mugwort
pollen extract (10 mg of proteins) was modified by KCNO treatment according to Mistrello et al.8
The modified sample, designated C-Av, was dialyzed against water and concentrated to a protein
concentration of 1 mg/ml. The same protein quantities were used in the modifications with 400 mM
succinic or maleic anhydride, according to a previously described procedure.12 The final samples,
designated M-Av and S-Av, were dialyzed against water and lyophilized. The protein concentration
was determined by the Bradford method.23
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Determination of amino groups
The number of amino groups in the control and modified samples, after exposure to the acidic
conditions of the gut, without the addition of pepsin, was determined using 2,4,6-trinitrobenze-
nesulfonic acid (TNBS) as the reagent according to a previously described procedure.17 The results
are expressed as means of three different determinations and for the modified samples as a percent-
age of the number of amino groups determined for the unmodified sample (expressed as 100 %).
Digestion of samples in SF and SGF
Digestion of samples in SF and SGF was performed as already described.16
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis and blotting to nitrocellulose mem-
brane
SDS PAGE was carried out according to Laemmli24 using a Hoefer Scientific Instrumentation
apparatus with a discontinuous buffer system. Native and modified samples in the same quantity of
10 g per well (Av, C-Av, S-Av and M-Av) were diluted in sample buffer (5 % -mercaptoethanol)
and boiled for 5 min before the run. The protein components were resolved on an 18 % gel, with a
standard protein mixture for mol. wt. reference, at 80 V for 1 h and 250 V for a further 2 h. The gels
were stained with Coomassie Brilliant Blue R-250 to visualize the separated proteins.
Resolved components were blotted by a semi-dry electroblotter onto nitrocellulose paper. The
transferred proteins were blocked in TBS – 0.1 % Tween 20 for 1 h and dried until development.
Human sera
The sera from 25 patients allergic to mugwort pollen, with a documented clinical history of
mugwort pollen allergy and with no recorded immunotherapy to mugwort pollen, were pooled for
the CAP inhibition experiment. The patients were allergic to mugwort pollen, with documented
clinical histories of allergic rhinitis, allergic asthma, allergic rhinoconjunctivitis and allergic con-
junctivitis in accordance with the Position Paper for the revised nomenclature for allergy.25 Sera
from five non-atopic persons were pooled and used as a control.
IgE detection
IgE bands were probed in immunoblot. The proteins were resolved by SDS PAGE, transferred
to nitrocellulose paper as described above and determined by probing with 10-fold diluted pooled
human sera in a diluting buffer (TBS – 0.1 % BSA). As secondary antibodies, alkaline phosphatase
labelled monoclonal anti human IgE (Sigma Chemical Co., St Louis MO, USA) was used. The bind-
ing patterns were visualized with a substrate solution consisting of 1.5 mg BCIP (5-bromo-4-chlo-
ro-3-indolyl phosphate) and 3 mg NBT (nitroblue tetrazolium) in 10 mL of 100 mM Tris buffer, con-
taining 150 mM NaCl, and 5 mM MgCl2, pH 9.6.
CAP inhibition of IgE binding from a pool of allergic patients sera
For CAP inhibition, samples of mugwort pollen extract, maleylated, succinylated and carba-
mylated allergoids were diluted in PBS to a concentration of 20 g/mL. The saliva (2 minutes
treated samples) and SGF (1 hour treated samples) exposed samples were diluted to the same vol-
ume, as were the untreated proteins. As controls, the human serum pool was incubated with saliva or
SGF solutions diluted to the same volume as the samples and ovalbumin in the same concentration
as the samples, or with PBS alone. Human serum from subjects with skin tests negative to mugwort
pollen extract was also used as a negative control. After overnight incubation, the IgE inhibiton was
determined by a UniCap (Pharmacia, Sweden) according to the manufacturer's instructions. The
percent of inhibition was calculated as described previously
26 and from the appropriate positive
control.
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U ovom radu su prikazani rezultati ispitivawa stabilnosti tri tipa alergoida
polena pelina u simuliranom `eluda~nom soku. Koriste}i kalijum-cijanat, anhidrid
}ilibarne i anhidrid maleinske kiseline, napravqeni su alergoidi polena pelina
(Artemisia vulgaris). Saliva i `eluda~ni sok su simulirani na osnovu evropske farma-
kopeje. Biohemijske i imunohemijske osobine derivata, posle izlagawa razli~itim
uslovima, pra}ene su: odre|ivawem broja slobodnih amino grupa u reakciji sa TNBS,
SDS PAG elektroforezom, imunoblotom i odre|ivawem pelin-specifi~nog imuno-
globulina E (IgE). Izlagawe salivi u trajawu od 2 minuta ne uti~e na biohemijske i
imunohemijske osobine derivata. U kiseloj sredini `eluda~nog soka ne dolazi do
zna~ajnog demaleilovawa i desukcinilovawa. ^ak i posle ~etvoro~asovnog izlagawa,
taj procenat je u opsegu 10–30 %. Alergoidi pelina se trenutno digestuju pepsinom, sa
izuzetkom visoko rezistentne proteinske trake molekulske mase 28–35 kD, koja odgo-
vara va`nom IgE-vezuju}em proteinu polena pelina. Imunoblotom i CAP-inhibicijom
je pokazano da, u okviru fiziolo{kih uslova, ne dolazi do stvarawa novih IgE-ve-
zuju}ih epitopa. Hemijska stabilnost modifikovanih derivata u simuliranim uslo-
vima `eluda~nog soka omogu}uje da se tokom imunoterapije mogu primewivati ve}e
doze alergoida nego nemodifikovanog ekstrakta polena pelina.
(Primqeno 31. avgusta 2005, revidirano 30. januara 2006)
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